{"id":"https://openalex.org/W3097078026","doi":"https://doi.org/10.1182/blood-2020-142518","title":"Mechanisms Regulating Myeloma Cell Responsiveness to Antisense Oligonucleotides Targeting IRF4","display_name":"Mechanisms Regulating Myeloma Cell Responsiveness to Antisense Oligonucleotides Targeting IRF4","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3097078026","doi":"https://doi.org/10.1182/blood-2020-142518","mag":"3097078026"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-142518","doi":"https://doi.org/10.1182/blood-2020-142518","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-142518","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027607604","display_name":"Ryosuke Shirasaki","orcid":"https://orcid.org/0009-0000-5629-1394","observed_orcids":["https://orcid.org/0009-0000-5629-1394"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryosuke Shirasaki","raw_affiliation_strings":["Broad Institute of MIT and Harvard, Cambridge, MA","Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Broad Institute of MIT and Harvard, Cambridge, MA","institution_ids":["https://openalex.org/I107606265"]},{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014388276","display_name":"Esperanza Macarena Algar\u00edn","orcid":"https://orcid.org/0000-0002-5112-341X","observed_orcids":["https://orcid.org/0000-0002-5112-341X"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Esperanza M Algar\u00edn","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005661878","display_name":"Ricardo De Matos Simoes","orcid":"https://orcid.org/0000-0002-1700-5276","observed_orcids":["https://orcid.org/0000-0002-1700-5276"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ricardo De Matos Simoes","raw_affiliation_strings":["Broad Institute of MIT and Harvard, Cambridge, MA","Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Broad Institute of MIT and Harvard, Cambridge, MA","institution_ids":["https://openalex.org/I107606265"]},{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049971068","display_name":"Sondra L. Downey-Kopyscinski","orcid":"https://orcid.org/0000-0003-4203-3583","observed_orcids":["https://orcid.org/0000-0003-4203-3583"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sondra L. Downey-Kopyscinski","raw_affiliation_strings":["Broad Institute of MIT and Harvard, Cambridge, MA","Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Broad Institute of MIT and Harvard, Cambridge, MA","institution_ids":["https://openalex.org/I107606265"]},{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004664267","display_name":"Shizuka Yamano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shizuka Yamano","raw_affiliation_strings":["Broad Institute of MIT and Harvard, Cambridge, MA","Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Broad Institute of MIT and Harvard, Cambridge, MA","institution_ids":["https://openalex.org/I107606265"]},{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107517383","display_name":"Xiaolin Luo","orcid":"https://orcid.org/0009-0008-4975-0407","observed_orcids":["https://orcid.org/0009-0008-4975-0407"]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaolin Luo","raw_affiliation_strings":["Ionis Pharmaceuticals, Inc., Carlsbad, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ionis Pharmaceuticals, Inc., Carlsbad, CA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100395867","display_name":"Youngsoo Kim","orcid":"https://orcid.org/0000-0002-7592-1387","observed_orcids":["https://orcid.org/0000-0002-7592-1387"]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Youngsoo Kim","raw_affiliation_strings":["Ionis Pharmaceuticals, Inc., Carlsbad, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ionis Pharmaceuticals, Inc., Carlsbad, CA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Robert MacLeod","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert MacLeod","raw_affiliation_strings":["Ionis Pharmaceuticals, Inc., Carlsbad, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ionis Pharmaceuticals, Inc., Carlsbad, CA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012712111","display_name":"Constantine S. Mitsiades","orcid":"https://orcid.org/0000-0003-2321-8005","observed_orcids":["https://orcid.org/0000-0003-2321-8005"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Constantine S. Mitsiades","raw_affiliation_strings":["Broad Institute of MIT and Harvard, Cambridge, MA","Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Broad Institute of MIT and Harvard, Cambridge, MA","institution_ids":["https://openalex.org/I107606265"]},{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"Supplement 1","first_page":"32","last_page":"32"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9419999718666077},{"id":"https://openalex.org/keywords/irf4","display_name":"IRF4","score":0.9240000247955322},{"id":"https://openalex.org/keywords/antisense-oligonucleotides","display_name":"antisense oligonucleotides","score":0.9990000128746033},{"id":"https://openalex.org/keywords/transcription-factor-targeting","display_name":"transcription factor targeting","score":0.5809999704360962},{"id":"https://openalex.org/keywords/undruggable-targets","display_name":"undruggable targets","score":0.7839999794960022},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.39500001072883606},{"id":"https://openalex.org/keywords/transcriptional-regulation","display_name":"transcriptional regulation","score":0.32499998807907104},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.39399999380111694},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.781000018119812},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.8320000171661377},{"id":"https://openalex.org/keywords/thalidomide-derivatives","display_name":"thalidomide derivatives","score":0.9599999785423279},{"id":"https://openalex.org/keywords/glucocorticoids","display_name":"glucocorticoids","score":0.984000027179718},{"id":"https://openalex.org/keywords/mesenchymal-stem-cells","display_name":"mesenchymal stem cells","score":0.9610000252723694},{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.45899999141693115},{"id":"https://openalex.org/keywords/crispr-screening","display_name":"CRISPR screen","score":0.5740000009536743}],"concepts":[{"id":"https://openalex.org/C12652872","wikidata":"https://www.wikidata.org/wiki/Q18027997","display_name":"IRF4","level":4,"score":0.9024214744567871},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5741667151451111},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.49333205819129944},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.47835013270378113},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.4299785792827606},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4190284013748169},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.41669604182243347},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.37665361166000366},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.36152589321136475},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.34856200218200684},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.25081223249435425},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.20060598850250244},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.13464584946632385},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-142518","doi":"https://doi.org/10.1182/blood-2020-142518","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-142518","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2974656422","https://openalex.org/W2073679029","https://openalex.org/W3122660020","https://openalex.org/W7148900796","https://openalex.org/W2987205139","https://openalex.org/W4406107698","https://openalex.org/W1981403111","https://openalex.org/W2990185561","https://openalex.org/W7206212669","https://openalex.org/W4405042625"],"abstract_inverted_index":{"Functional":[0],"genomics":[1],"studies":[2,329,450],"from":[3,289],"our":[4,446,623],"group":[5],"and":[6,34,38,45,82,111,133,175,195,303,324,509,537,575,611,634],"others,":[7],"including":[8],"CRISPR":[9,328,449],"screens,":[10],"have":[11,619],"documented":[12],"that":[13,121],"interferon":[14],"regulatory":[15],"factor":[16,23],"4":[17],"(IRF4)":[18],"is":[19,68],"a":[20,122,247,293,517,582,636,690],"critical":[21],"transcription":[22],"(TF)":[24],"for":[25,48,144,201,236,385,392,622,638],"multiple":[26],"myeloma":[27],"(MM)":[28],"cells":[29,50,96,152,160,320,377,387,426,598],"in":[30,32,35,78,84,109,163,181,198,213,246,262,272,281,372,388,424,434,492,591,631],"preclinical":[31],"vitro":[33,164,214,263,389],"vivo":[36,85],"models;":[37],"one":[39],"of":[40,94,124,173,220,249,256,318,353,366,404,438,443,453,469,488,502,512,522,531,539,548,572,578,585,588,594,608,617,626,629,689],"the":[41,92,315,342,347,436,476,485,565,592,609,627],"top":[42],"most":[43,145],"pronounced":[44],"recurrent":[46],"dependencies":[47,384],"MM":[49,95,110,139,146,237,251,258,282,307,343,354,386,393,425,459,555,561,597,632],"vs.":[51,148,378,394],"other":[52,379,645],"neoplasias.":[53],"IRF4":[54,67,117,183,190,266,311,348,358,419,463,513,524,566,573,579,630,639],"lacks":[55],"known":[56],"ligand-binding":[57],"pocket(s)":[58],"amenable":[59],"to":[60,89,97,100,189,203,240,265,310,322,330,346,401,462,533,564],"selective":[61],"inhibition":[62],"by":[63,178,193,286,408,418,467,641],"small-molecule":[64],"pharmacological":[65],"agents.":[66],"thus":[69],"considered,":[70],"as":[71,74,113,211,383],"many":[72,454],"TFs,":[73],"\"undruggable\".":[75],"Recent":[76],"progress":[77],"antisense":[79],"oligonucleotides":[80],"(ASOs)":[81],"their":[83,105,261],"properties":[86],"motivated":[87],"us":[88],"systematically":[90],"evaluate":[91],"response":[93,264,345,461,563],"anti-IRF4":[98,125],"ASOs,":[99,312],"obtain":[101,299],"direct":[102,620],"insights":[103,300],"into":[104,116,301],"potential":[106],"therapeutic":[107,646],"applications":[108],"also":[112,325],"functional":[114,612],"probes":[115],"biology.":[118],"We":[119],"observed":[120,169],"panel":[123,248],"ASOs":[126,464,589,642],"(but":[127],"not":[128,557],"control":[129,361],"ASO)":[130,362],"exhibited":[131],"dose-":[132],"time-dependent":[134],"activity":[135,166,210,442,587],"against":[136,150],"genotypically":[137],"diverse":[138,489],"cell":[140,252,259,283,308,344,355,460,562],"lines":[141,147],"(sub-uM":[142],"IC50s":[143],">10uM":[149],"non-MM":[151,395],"lacking":[153],"IRF4,":[154],"e.g.":[155,520],"HS5":[156],"bone":[157],"marrow":[158],"stromal":[159],"[BMSCs]).":[161],"Major":[162],"anti-MM":[165,209,441,535,586],"could":[167],"be":[168],"within":[170],"3-5":[171],"days":[172],"treatment;":[174],"was":[176,278,465,556],"preceded":[177],"significant":[179,270],"decrease":[180],"intracellular":[182,482,570],"protein":[184],"levels.":[185],"Importantly,":[186,414,544],"24-hour":[187],"exposure":[188,215],"ASO":[191,267,359,420,493,532,574],"(followed":[192],"washout":[194],"subsequent":[196],"culture":[197],"ASO-free":[199],"media":[200,288],"up":[202],"6":[204,217,250],"days)":[205],"can":[206],"induce":[207],"similar":[208],"continuous":[212],"over":[216],"days.":[218],"Combinations":[219],"IRF4-ASO":[221],"with":[222,274,357,369,428,456,484,553,559,599,615],"several":[223,415],"established":[224],"(e.g.":[225,233,495],"proteasome":[226],"inhibitor,":[227],"thalidomide":[228],"derivative,":[229],"glucocorticoids)":[230],"or":[231,242,291,337,374,397,412,500,546,643],"investigational":[232],"venetoclax)":[234],"agents":[235],"result":[238],"led":[239],"enhanced":[241],"even":[243,590],"synergistic":[244],"effects":[245],"lines.":[253],"For":[254],"some":[255],"these":[257],"lines,":[260],"had":[268],"statistically":[269],"attenuation":[271],"co-cultures":[273,439],"BMSCs:":[275],"this":[276],"effect":[277],"partially":[279],"recapitulated":[280],"monocultures":[284],"supplemented":[285],"conditioned":[287],"BMSCs":[290],"(to":[292],"lesser":[294],"extent)":[295],"rhIL6":[296],"treatment.":[297],"To":[298],"cell-autonomous":[302],"nonautonomous":[304],"mechanisms":[305],"regulating":[306],"responses":[309],"we":[313],"examined":[314],"transcriptional":[316,351],"profiles":[317],"MM.1S":[319],"exposed":[321],"ASOs;":[323],"performed":[326],"genome-scale":[327,448],"define":[331],"genes":[332,368,416,455,490,550],"whose":[333],"editing":[334],"(loss-of-function,":[335],"LOF)":[336],"activation":[338],"(gain-of-function,":[339],"GOF)":[340],"alter":[341],"ASOs.":[349],"The":[350],"signature":[352],"treatment":[356,421],"(vs.":[360],"comprised":[363],"distinct":[364],"clusters":[365],"downregulated":[367,417],"preferential":[370],"expression":[371],"normal":[373],"malignant":[375],"plasma":[376],"lineages;":[380],"CRISPR-validated":[381],"roles":[382],"(preferentially":[390],"essential":[391],"tumors;":[396],"pan-essential);":[398],"and/or":[399],"proximity":[400],"large":[402],"areas":[403],"chromatin":[405],"accessibility":[406],"(defined":[407],"H3K27Ac":[409],"genome-wide":[410],"ChIP-Seq":[411],"ATAC-Seq).":[413],"are":[422],"upregulated":[423],"cocultured":[427],"BMSCs,":[429],"possibly":[430],"explaining":[431],"at":[432],"least":[433],"part":[435],"impact":[437],"on":[440],"ASO.":[444],"In":[445],"integrated":[447,606],"(and":[451],"validation":[452],"individual":[457,549],"sgRNAs),":[458],"attenuated":[466],"LOF":[468,487,545],"endonuclease":[470],"RNase":[471],"H1":[472],"(RNASEH1;":[473],"which":[474],"degrades":[475],"target":[477],"RNA":[478],"when":[479],"it":[480],"establishes":[481],"hybrids":[483],"ASOs);":[486],"involved":[491],"endocytosis":[494],"IGF2R,":[496],"PICALM,":[497],"SH3GL1,":[498],"RAB5C)":[499],"regulation":[501],"chondroitin/heparan":[503],"sulfate":[504],"(SLC35B2,":[505],"B3GAT3,":[506],"B4GALT7,":[507],"ALG5":[508],"ALG6);":[510],"GOF":[511,538,547],"itself":[514],"(likely":[515],"reflecting":[516],"\"stoichiometric\"":[518],"effect,":[519],"induction":[521],"higher":[523,529],"mRNA":[525,580],"levels":[526],"may":[527],"require":[528],"concentrations":[530],"maintain":[534],"effect);":[536],"exocytosis-related":[540],"genes(e.g.":[541],"CLU,":[542],"QPCT).":[543],"typically":[551],"associated":[552,558,614],"high-risk":[554],"decreased":[560],"ASOs:":[567],"therefore,":[568],"retaining":[569],"accumulation":[571],"productive":[576],"knockdown":[577],"remains":[581],"primary":[583],"driver":[584],"context":[593],"biologically":[595],"aggressive":[596],"\"high-risk\"":[600],"features.":[601],"Our":[602],"results":[603],"provide":[604,635],"comprehensive":[605],"assessment":[607],"molecular":[610],"landscapes":[613],"dysregulation":[616],"IRF4;":[618],"implications":[621],"mechanistic":[624],"understanding":[625],"role":[628],"biology;":[633],"framework":[637],"targeting":[640],"potentially":[644],"approaches.":[647],"Disclosures":[648],"Downey-Kopyscinski:":[649],"Rancho":[650],"BioSciences,":[651],"LLC:":[652],"Current":[653,658,663,668],"Employment.":[654,659,664,669],"Luo:Ionis":[655],"Pharmaceuticals,":[656,661,666,709],"Inc.:":[657,662,667,710],"Kim:Ionis":[660],"MacLeod:Ionis":[665],"Mitsiades:Arch":[670],"Oncology:":[671],"Research":[672,675,681,684,693,698,706],"Funding;":[673,676,682,685,694,699,707],"Sanofi:":[674],"FIMECS:":[677],"Consultancy,":[678,702,711],"Honoraria;":[679,703],"Karyopharm:":[680],"Abbvie:":[683],"Takeda:":[686],"Other:":[687],"employment":[688],"relative;":[691],"TEVA:":[692],"Janssen/Johnson":[695],"&":[696],"Johnson:":[697],"Fate":[700],"Therapeutics:":[701],"EMD":[704],"Serono:":[705],"Ionis":[708],"Honoraria.":[712]},"counts_by_year":[{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}